# A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

> **NCT00916669** · PHASE2 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** enoxaparin sodium

## Key facts

- **NCT ID:** NCT00916669
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** sponsor withdrew funding prior to patient enrollment
- **Last updated:** 2013-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916669, "A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00916669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*